How the Peptide Semax Protects the Brain During Stroke: An Immune System Connection
Semax protects rat brains during stroke primarily by boosting immune response gene expression, particularly antigen presentation and interferon signaling pathways.
Quick Facts
What This Study Found
The synthetic peptide Semax — composed of the ACTH(4-7) fragment plus the tripeptide Pro-Gly-Pro (PGP) — protects rat brains during ischemic stroke primarily through immune system modulation. Genome-wide transcriptome analysis of the cerebral cortex revealed that Semax's most significant effect was on immune response genes.
Specifically, Semax enhanced antigen presentation pathways, intensified interferon signaling already activated by ischemia, affected immunoglobulin synthesis, and significantly increased expression of immunoglobulin heavy chain genes. It also strongly affected cytokine, stress response, and ribosomal protein genes after stroke.
Interestingly, the PGP tripeptide component alone had the opposite effect — it suppressed immune activity and neurotransmission in the central nervous system. This suggests the two components of Semax may have distinct and potentially complementary roles in neuroprotection.
Key Numbers
Genome-wide biochip analysis · Focal cerebral ischemia model · Key pathways: antigen presentation, interferon signaling, immunoglobulin synthesis · PGP: suppressed immune activity + neurotransmission
How They Did This
Rats with focal cerebral ischemia (middle cerebral artery occlusion) were treated with Semax or PGP. Researchers performed genome-wide transcriptome analysis of the cerebral cortex using biochip arrays, identified differentially expressed genes (DEGs), and used the bioinformatic tool Ingenuity iReport to map DEGs to biological processes and signaling pathways.
Why This Research Matters
Stroke kills millions annually, and effective neuroprotective treatments remain limited. This study provides the first genome-wide view of how Semax protects the brain during stroke, revealing that its mechanism involves neuroimmune crosstalk — the communication between the nervous and immune systems. Understanding this mechanism could lead to better-designed peptide therapies for stroke and help explain why Semax has shown neuroprotective effects in clinical use in Russia.
The Bigger Picture
The idea that brain protection during stroke involves immune system modulation is gaining traction in neuroscience. This study positions Semax as a peptide that works through neuroimmune crosstalk — the emerging field studying how the nervous and immune systems communicate. As the Western medical community increasingly investigates peptide-based neuroprotection, understanding Semax's mechanism could inform the development of new stroke treatments.
What This Study Doesn't Tell Us
This is an animal study in rats — results may not directly translate to human stroke patients. The study examines gene expression changes (transcriptome), not protein levels or functional outcomes, so the actual protective effect cannot be directly measured from this data alone. The specific mechanisms by which immune modulation leads to neuroprotection remain unclear. Semax is used clinically in Russia but lacks FDA approval and large-scale clinical trial data in Western countries.
Questions This Raises
- ?Do the gene expression changes seen with Semax translate to measurable improvements in stroke outcomes and functional recovery?
- ?Why do the Semax and PGP components have opposing effects on immune activity, and how does this combination produce neuroprotection?
- ?Could Semax or similar peptides be tested in rigorous Western clinical trials for acute stroke treatment?
Trust & Context
- Key Stat:
- Immune response: most affected process Genome-wide transcriptome analysis showed Semax's primary neuroprotective mechanism involves boosting immune signaling genes during ischemic brain injury
- Evidence Grade:
- This is a preclinical animal study examining gene expression changes. While the genome-wide approach is comprehensive, the findings are mechanistic rather than outcome-based, and the rat model has limited direct human translatability.
- Study Age:
- Published in 2017, this study provides important mechanistic data on Semax. While Semax has been used clinically in Russia for years, it remains unapproved in Western countries, and this type of mechanistic research continues to build the evidence base.
- Original Title:
- Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.
- Published In:
- Molecular genetics and genomics : MGG, 292(3), 635-653 (2017)
- Authors:
- Medvedeva, Ekaterina V, Dmitrieva, Veronika G(2), Limborska, Svetlana A(2), Myasoedov, Nikolay F, Dergunova, Lyudmila V
- Database ID:
- RPEP-03395
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is Semax and is it available as a medication?
Semax is a synthetic peptide developed in Russia, consisting of a fragment of the stress hormone ACTH plus a tripeptide called PGP. It's approved and used in Russia as a neuroprotective agent for stroke and cognitive enhancement, typically given as a nasal spray. It is not approved by the FDA or EMA and is not available through standard pharmacies in Western countries.
How does boosting the immune response protect the brain during a stroke?
During a stroke, the brain's immune response needs to walk a fine line — some immune activation helps clear damaged cells and fight infection, but too much inflammation causes additional damage. Semax appears to enhance specific protective immune pathways (like antigen presentation and interferon signaling) that help the brain mount a controlled defensive response rather than a damaging inflammatory one.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03395APA
Medvedeva, Ekaterina V; Dmitrieva, Veronika G; Limborska, Svetlana A; Myasoedov, Nikolay F; Dergunova, Lyudmila V. (2017). Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.. Molecular genetics and genomics : MGG, 292(3), 635-653. https://doi.org/10.1007/s00438-017-1297-1
MLA
Medvedeva, Ekaterina V, et al. "Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats.." Molecular genetics and genomics : MGG, 2017. https://doi.org/10.1007/s00438-017-1297-1
RethinkPeptides
RethinkPeptides Research Database. "Semax, an analog of ACTH(4-7), regulates expression of immun..." RPEP-03395. Retrieved from https://rethinkpeptides.com/research/medvedeva-2017-semax-an-analog-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.